MedTrace Logo

The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring

NCT02647164 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 360

Last updated 2016-01-06

No results posted yet for this study

Summary

The purpose of this study is to assess the value of circulating tumor cells (CTC)for non-small cell lung cancer in the postoperative recurrence monitoring by comparing the CTCs, CT and tumor markers at different time points.The time of CTC and carcinoembryonic antigen(CEA) detection is baseline, 2\~7 days, 3 months, 6 months, 12 months, 24 months, 36 months after the surgery. And the time of CT detection is 6 months, 12 months, 24 months, 36 months after the surgery.

Conditions

  • Non-small-cell Lung Carcinoma

Sponsors & Collaborators

  • GenoSaber

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02647164 on ClinicalTrials.gov